Compare PYXS & OGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PYXS | OGI |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 132.2M |
| IPO Year | 2021 | 2015 |
| Metric | PYXS | OGI |
|---|---|---|
| Price | $3.24 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 979.1K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,858,000.00 | N/A |
| Revenue This Year | N/A | $20.10 |
| Revenue Next Year | $7,043.98 | $13.92 |
| P/E Ratio | ★ N/A | $13.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $0.85 |
| 52 Week High | $5.55 | $2.24 |
| Indicator | PYXS | OGI |
|---|---|---|
| Relative Strength Index (RSI) | 55.72 | 61.75 |
| Support Level | $1.37 | $1.18 |
| Resistance Level | $3.45 | $1.69 |
| Average True Range (ATR) | 0.41 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 66.19 | 52.50 |
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.